Osteonecrosis of the Jaw: More Research Needed

Authors


  • Dr Drezner receives research support from Eli Lilly & Co., Merck, and Roche. Dr Eisman receives research support and/or provides consulting to Amgen, deCode, Eli Lilly & Co., GE-Lunar, Merck, Sharpe & Dohme, Novartis, Organon, Pfizer, Roche-GSK, Sanofi-Avenits, and Servier. Dr Goldring receives research support from Boehringer Ingelheim and holds consultancies with Amgen, Genzyme, and Omeros. He also serves on the Board of Directors for Telik, the Osteoarthritis Advisory Board for Genzyme, and the Abbott Scholars Advisory Board for Abbott. Dr Shane receives research support from Novartis. Dr Silverman receives research support from Aventis, Eli Lilly & Co., Novartis, Roche, and Wyeth. He serves as a consultant to Merck, Procter & Gamble, Roche, and Wyeth. He also serves on the Speakers' Bureau for Eli Lilly & Co., Merck, and Procter & Gamble. Drs Christakos and Dr Pendrys state that they have no conflicts of interest.

No abstract is available for this article.

Ancillary